Treatment of GLP-1 for Diabetic Bariatric Patients

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Geisinger Clinic
• Collaborator: Novo Nordisk A/S

Criteria

Inclusion Criteria:

1. Candidates for Roux-en-Y Gastric Bypass Surgery with an established diagnosis of Type 2 diabetes requiring insulin treatment for glycemic control

2. Ability to provide informed consent before any trial-related activities

Exclusion Criteria:

1. Prior metabolic surgery procedure

2. Use of GLP-1 analogues for diabetes treatment at the time of recruitment

3. Known or suspected allergy to semaglutide or the excipients in semaglutide, or related products.

4. Contraindications to semaglutide which include a personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia syndrome-2 (MEN-2)

5. Previously randomized for participation in this trial.

6. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures.

7. Type 1 diabetes